Effects of selective serotonin reuptake inhibitors on rating-scale-assessed suicidality in adults with depression

Abstract

BackgroundSelective serotonin reuptake inhibitors (SSRIs) have been claimed to elicit or aggravate suicidal ideation.AimsTo explore the effect of SSRIs on the suicidality item of the Hamilton Rating Scale for Depression (HRSD).MethodWe undertook a patient-level mega-analysis of adults with depression participating in industry-sponsored studies of sertraline, paroxetine or citalopram, comparing patients on an SSRI (n = 5681) with those on placebo (n = 2581) with respect to HRSD-rated suicidality. Separate analyses were conducted for young adults (age 18–24; n = 537) and adults (age ≥25; n = 7725).ResultsAmong adults, the reduction in mean rating of suicidality was larger and the risk for aggravation of suicidality lower in patients receiving an SSRI from week 1 and onwards. In young adults, SSRI treatment neither reduced nor increased suicidality ratings relative to placebo at the end-point.ConclusionsThe net effect of SSRIs on suicidality appears beneficial in people above the age of 24 and neutral in those aged 18–24.Declaration of interestF.H. has received speaker's fees from Servier. E.E. has previously been on the advisory boards and/or received speaker's honoraria and/or research grants from Eli Lilly, GlaxoSmithKline, Servier and Lundbeck.